XML 40 R28.htm IDEA: XBRL DOCUMENT v3.23.1

Revenue Recognition and Accounts Receivable (Tables)

3 Months Ended

Mar. 31, 2023

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table presents the Company’s net sales by product category for each of our reportable segments for the three months ended March 31, 2023 and 2022, respectively:

(In millions)			Three Months Ended March 31, 2023
Product Category			Developed Markets						Greater China						JANZ						Emerging Markets						Total
Brands			$	1,232.0					$	562.4					$	190.3					$	435.6					$	2,420.3
Complex Gx			129.9						—						6.1						0.1						136.1
Generics			808.5						2.2						145.8						206.2						1,162.7
Total			$	2,170.4					$	564.6					$	342.2					$	641.9					$	3,719.1

(In millions)			Three Months Ended March 31, 2022
Product Category			Developed Markets						Greater China						JANZ						Emerging Markets						Total
Brands			$	1,298.7					$	569.7					$	249.0					$	436.7					$	2,554.1
Complex Gx and Biosimilars			364.1						—						10.3						16.4						390.8
Generics			813.3						3.4						164.5						252.1						1,233.3
Total			$	2,476.1					$	573.1					$	423.8					$	705.2					$	4,178.2

____________

(a)Amounts for the three months ended March 31, 2023 include the unfavorable impact of foreign currency translations compared to the prior year period.

(b)Amounts for the three months ended March 31, 2022 include $164.8 million related to the biosimilars business which was subsequently contributed to Biocon Biologics in November 2022. The Company has not recognized the results of the biosimilars business in its consolidated financial statements subsequent to November 29, 2022.

The following table presents net sales on a consolidated basis for select key products for the three months ended March 31, 2023 and 2022:

						Three months ended March 31,
(In millions)						2023						2022
Select Key Global Products
Lipitor ®						$	417.9					$	440.1
Norvasc ®						202.7						207.8
Lyrica ®						144.3						171.7
Viagra ®						115.0						129.8
EpiPen® Auto-Injectors						95.8						88.8
Celebrex ®						88.8						85.2
Creon ®						72.7						74.7
Effexor ®						64.6						77.5
Zoloft ®						56.5						73.1
Xalabrands						46.7						53.0
Select Key Segment Products
Dymista ®						$	53.2					$	44.0
Yupelri ®						47.0						43.7
Xanax ®						39.7						40.0
Amitiza ®						36.6						41.8

____________

(a)The Company does not disclose net sales for any products considered competitively sensitive.

(b)Products disclosed may change in future periods, including as a result of seasonality, competition or new product launches.

(c)Amounts for the three months ended March 31, 2023 include the unfavorable impact of foreign currency translations compared to the prior year period.

Variable Consideration and Accounts Receivable

The following table presents a reconciliation of gross sales to net sales by each significant category of variable consideration during the three months ended March 31, 2023 and 2022, respectively:

									Three Months Ended
									March 31,
(In millions)															2023						2022
Gross sales															$	6,273.0					$	7,198.3
Gross to net adjustments:
Chargebacks															(1,350.7)						(1,584.2)
Rebates, promotional programs and other sales allowances															(992.2)						(1,205.9)
Returns															(50.4)						(82.6)
Governmental rebate programs															(160.6)						(147.4)
Total gross to net adjustments															$	(2,553.9)					$	(3,020.1)
Net sales															$	3,719.1					$	4,178.2

Schedule of Accounts Receivable, Net

Such allowances were comprised of the following at March 31, 2023 and December 31, 2022, respectively:

(In millions)			March 31, 2023						December 31, 2022
Accounts receivable, net			$	1,739.9					$	1,798.7
Other current liabilities			851.5						888.8
Total			$	2,591.4					$	2,687.5

Accounts receivable, net was comprised of the following at March 31, 2023 and December 31, 2022, respectively:

(In millions)			March 31, 2023						December 31, 2022
Trade receivables, net			$	3,021.9					$	3,243.8
Other receivables			475.6						570.7
Accounts receivable, net			$	3,497.5					$	3,814.5

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

+ Details

Name:	us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration